PRINSTON PHARMACEUTICAL ANNOUNCES THE APPROVAL OF GENERIC RISPERDAL® TABLETS IN THE UNITED STATES
CRANBURY, NJ – May 4, 2015 – Prinston Pharmaceutical, Inc. is proud to announce that the U.S. Food and Drug Administration (FDA) have approved its generic equivalent of Risperdal® (Risperidone Tablets USP), 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg. Prinston will be launching Risperidone in the third quarter of 2015 via its generic division, Solco Healthcare, LLC.
"We are pleased to receive FDA approval of generic valsartan and hydrochlorothiazide tablets, a product that was self-developed and manufactured in our parent company’s Linhai, China facility," said Jun Du, Prinston’s CEO. "With a pipeline of over 34 Abbreviated New Drug Applications (ANDAs) pending approval, we continue to strengthen our presence within the US generic market by providing high value medicines at affordable prices.”
According to IMS Health (NSP), U.S. brand and generic sales of risperidone tablets products were approximately $123.7 million for the 12 months ending in April 2015.
About Prinston Pharmaceutical, Inc. Prinston Pharmaceutical, Inc. is a fast growing, emerging global pharmaceutical company, located in Cranbury, New Jersey, USA. We are a fully integrated pharmaceutical company engaged in product development, product registration, manufacturing, marketing and sales of high quality affordable generic prescription products to our customers. Our highly experienced R&D team meets market needs through innovation, rapidly bringing high quality products to the US market, to help patients get the best pharmaceutical products at an affordable cost. We deliver and maintain the highest quality standard and integrity in all of our products, which are manufactured by the company or its partners around the world in world-class cGMP (current Good Manufacturing Practices) manufacturing facilities.Tweet